Elevation Oncology Inc (NASDAQ:ELEV) shares, rose in value on Friday, June 20, with the stock price down by -1.01% to the previous day’s close as strong demand from buyers drove the stock to $0.38.
Actively observing the price movement in the last trading, the stock closed the session at $0.38. Referring to stock’s 52-week performance, its high was $3.28, and the low was $0.22. On the whole, ELEV has fluctuated by 16.12% over the past month.
With the market capitalization of Elevation Oncology Inc currently standing at about $22.57 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-15.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ELEV’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ELEV currently trading nearly 11.44% and 12.46% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.57, while the 7-day volatility ratio is showing 1.11% which for the 30-day chart, stands at 4.51%. Furthermore, Elevation Oncology Inc (ELEV)’s beta value is 1.46, and its average true range (ATR) is 0.02.
A comparison of Elevation Oncology Inc (ELEV) with its peers suggests the former has fared considerably weaker in the market. ELEV showed an intraday change of -1.01% in last session, and over the past year, it shrunk by -87.19%%.
Data on historical trading for Elevation Oncology Inc (NASDAQ:ELEV) indicates that the trading volumes over the past 3 months, they’ve averaged 1.76 million. According to company’s latest data on outstanding shares, there are 59.22 million shares outstanding.
Nearly 10.50% of Elevation Oncology Inc’s shares belong to company insiders and institutional investors own 47.23% of the company’s shares. The stock has fallen by -32.28% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ELEV stock heading into the next quarter.
